[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pain-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pain-syndrome":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,82,116,141,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100625345","adding-amantadine-or-duloxetine-to-pregabalin-on-occurrence-of-post-mastectomy-pain-syndrome-100625345",false,"NCT07421427","Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome","The Effect of Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome; Randomized Controlled Study","Inclusion Criteria:\n\n* Age from 18 to 65 years.\n* American society of anesthesiologists (ASA) Physical status II, III.\n* Body mass index (BMI): (20-40) kg\u002Fm2.\n* Type of surgery: patients undergoing modified radical mastectomy for breast cancer.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Patients with Known sensitivity or contraindication to drug used in the study.\n* History of psychological disorders and\u002For chronic pain and drug abuse patients.\n* Previous administration of antidepressants, anticonvulsants, or opioids before surgery.\n* Severe respiratory or cardiac disorders.\n* Advanced liver or kidney disease.\n* Previous breast surgery","FEMALE","18 Years","65 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to evaluate the additive effect of Amantadine or Duloxetine to Pregabalin on development of post mastectomy pain syndrome",[27,28,29,30,31],"Amantadine","Duloxetine","Pregabalin","Mastectomy","Pain Syndrome","RECRUITING","2026-02-21",{"date":35,"type":36},"2026-02-24","ACTUAL",{"date":33,"type":36},{"date":39,"type":21},"2027-01-01",{"name":41,"class":42},"Cairo University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100385529","phase-2-ozone-therapy-in-chemotherapy-induced-peripheral-neuropathy-rct-o3npiq-100385529","NCT04299893","Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)","Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)","O3NPIQ","Inclusion Criteria:\n\n* 1\\. Adults \\> = 18 years old.\n* 2\\. Any kind of cancer in any stage, treated with any kind of chemotherapy, and life expectancy \\> = 6 months.\n* 3\\. Clinical diagnosis of painful chemotherapy-induced peripheral neuropathy, toxicity Grade 2 or higher according to the Common Toxicity Criteria for Adverse Events (CTCAE) from the National Cancer Institute of EEUU, v.5.0, for \\> = 3 months and without the inclusion of new treatments for pain and\u002For neuropathy for \\> = 1 month.\n* 4\\. \"Average pain\" \\> = 3\u002F10 according to the Brief Pain Inventory-Short Form (BPI-SF) \\> = 3 months beyond chemotherapy completion.\n* 5\\. Pregnant women cannot participate in the clinical trial.\n* 6\\. Before enrollment, women of childbearing potential should obtain a negative result in the serum or urine pregnancy test at the screening visit and accept the use of appropriate contraceptive methods at least from the 14 days prior to the first ozone therapy session up to 14 days after the last one.\n* 7\\. Patients who have signed and dated the study 's specific informed consent\n\nExclusion Criteria:\n\n* 1\\. Age \\\u003C 18 years old.\n* 2\\. Pregnancy at the time of enrollment.\n* 3\\. Women with childbearing potential who are unwilling to perform a pregnancy test and\u002For employ adequate contraception from the 14 days prior to the first ozone therapy session up to 14 days after the last one.\n* 4\\. Clinical suspicion that peripheral neuropathy (compressive or diabetic neuropathy) in the same area prior to receiving neurotoxic chemotherapy.\n* 5\\. Psychiatric illness or social situations that would limit compliance with study requirements.\n* 6\\. Those who are unable to fill in the scales used to measure quality of life variables\n* 7\\. Specific liver enzymes \\[Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) \\> 5 times the upper limit of normal\n* 8\\. Increased creatinine \\> 3 times the upper limit of normal.\n* 9\\. Hemodynamically or clinically unstable patients or uncontrolled severe illness.\n* 10\\. Uncontrolled cancer disease.\n* 11\\. Leptomeningeal carcinomatosis.\n* 12\\. Life expectancy \\\u003C 6 months\n* 13\\. Contraindication or disability for rectal ozone administration or to attend scheduled treatments.\n* 14\\. Known allergy to ozone.\n* 15.Patients who do not meet all the inclusion criteria.","ALL","100 Years",{"count":55,"type":21},42,[57,58],"PHASE2","PHASE3","The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain secondary to chemotherapy-induced peripheral neuropathy",[61,62,31],"Chemotherapy-induced Peripheral Neuropathy","Pain, Neuropathic",[64,65,66,67,68,69,70,71],"complementary and integrative medicine","cost-effectiveness ratio","chemotherapy-induced peripheral neuropathy","pain","ozone therapy","quality of life related to health","shared decision-making tool","randomized controlled trial","2025-08-25",{"date":74,"type":36},"2025-09-02",{"date":76,"type":36},"2020-11-30",{"date":78,"type":21},"2027-12-31",{"name":80,"class":42},"Bernardino Clavo, MD, PhD",2,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":43},"100412732","personalized-education-and-pain-response-in-chronic-pancreatitis-100412732","NCT04654377","Personalized Education and Pain Response in Chronic Pancreatitis","Impact of Personalized Education on Pain Response in Patients With Chronic Pancreatitis (PEPCP)","PEPCP","Inclusion Criteria:\n\n* Chronic pancreatitis of at least 3 years\n* At least 3 episodes of pain in the past 3 months\n* Age 18-60yrs\n* Both genders\n\nExclusion Criteria:\n\n* Acute pancreatitis episode at the time of enrolment.\n* Pancreatic cancer.\n* Other chronic diseases (including end organ damage related to diabetes).\n* Adverse life event in the family in the past 6 months.\n* Active substance use (alcohol, smoking, smokeless tobacco, Illicit drugs).\n* Pregnancy and lactation.\n* Psychiatric illness at enrolment or during follow-up, and\u002For concomitant intake of antidepressants and neuromodulators..","60 Years",{"count":92,"type":21},114,[24],"Pain mechanisms in chronic pancreatitis (CP) are heterogeneous and includes nociception, pancreatic neuropathy and central neuropathy\u002Fneuroplasty. These mechanisms could occur simultaneously in variable proportions and could explain why several patients develop recurrence of pain even after being treated by all the currently available modalities, such as antioxidants, endoscopic therapies and surgery.\n\nIn the studies by the investigators over the past 2 years, they observed that persistent pain in these patients was associated with varying grades of depression and poor quality of life. This was accompanied by alteration in the metabolites in the brain (anterior cingulate cortex, prefrontal cortex, hippocampus, and basal ganglia) as evidenced in magnetic resonance spectroscopy (MRS) of the brain. These areas in the brain are responsible for pain modulation, long-term pain memory and emotional responses to pain.\n\nWhen the investigators counselled these patients and explained their disease and possible outcomes based on their own clinical course, imaging and treatment response (personalized education\u002Fcounselling), they reported significant improvement in depression, quality of life parameters and, interestingly, also in pain. Further, there were changes in the metabolite parameters in the brain on MRS after personalized counselling\u002Feducation that was more similar to that of healthy controls.\n\nThis led to our hypothesis that better understanding of the disease and its outcomes by the patients could improve their coping capabilities and increase their pain thresholds. This could augment the pain responses of these patients to the other therapeutic modalities.\n\nWe will conduct this single blinded, placebo controlled, randomized controlled trial on patients with documented CP of over 3 years duration, who had at least 3 episodes of abdominal pain of over the past 3 months.",[96,31,97],"Chronic Pancreatitis","Depression, Anxiety",[99,67,100,101,102,103,104,105],"chronic pancreatitis","depression","anxiety","quality of life","metabolome","magnetic resonance spectroscopy","quantitative sensory testing","NOT_YET_RECRUITING","2025-07-27",{"date":109,"type":36},"2025-07-30",{"date":111,"type":21},"2025-08-01",{"date":113,"type":21},"2026-12-31",{"name":115,"class":42},"Asian Institute of Gastroenterology, India",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":43},"100584093","ultrasound-guided-multilevel-erectorspinae-plane-block-versus-thoracic-epidural-analgesia-for-prevention-of-post-mastectomy-pain-syndrome-for-breast-cancer-patients-100584093","NCT06884852","Ultrasound-guided Multilevel Erectorspinae Plane Block Versus Thoracic Epidural Analgesia for Prevention of Post Mastectomy Pain Syndrome for Breast Cancer Patients","Inclusion Criteria:\n\n* Female patients age ≥ 18 years and ≤ 65 Years.\n* Type of surgery; Modified Radical Mastectomy (MRM)\n* Physical status ASA II, III.\n* Body mass index (BMI): \\> 20 kg\u002Fm2 and \\\u003C 35 kg\u002Fm2.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Allergy or a contraindication to the drug used in the study, e.g. local anesthetics, opioids.\n* History of psychological disorders.\n* History of chronic pain.\n* Contraindication to regional anesthesia e.g. sepsis, peripheral neuropathies and coagulopathy.\n* Advanced chronic renal disease, which is defined as a chronic kidney disease (CKD) in which there is a severe reduction in glomerular filtration rate (GFR \\\u003C 30 ml\u002Fmin) and includes stages 4 and 5 of the CKD classification.\n* Decompensated cirrhosis, which is defined as an acute deterioration in liver function in a patient with cirrhosis and is characterized by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome, or variceal hemorrhage.\n* Severe heart disease which is defined as NYHA class iii (moderate symptoms with less than normal activity, marked limitation of function status) or NYHA class IV (severe symptoms with features of heart failure with minimal activity or at rest and severe limitation of functional status)\n* Severe lung disease which includes oxygen saturation of blood less than 92%, RR more than 20, FEV1\u002FFVC ratio less than 60%.\n* Pregnancy.",{"count":123,"type":21},44,[24],"The aim of this study is to compare the analgesic efficacy of multilevel erector spinae plane block (ESPB) vs thoracic epidural in modified radical mastectomy (MRM) regarding duration of analgesia, postoperative opioid consumption, effect on intraoperative fentanyl consumption, postoperative numerical pain rating scale and quality of life for the next 6 months.",[127,128,129,130,31,131],"Ultrasound","Multilevel Erector Spinae Plane Block","Thoracic Epidural Analgesia","Post Mastectomy","Breast Cancer Patients","2025-05-18",{"date":134,"type":36},"2025-05-21",{"date":136,"type":36},"2025-03-20",{"date":138,"type":21},"2026-03-01",{"name":140,"class":42},"National Cancer Institute, Egypt",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":52,"minAge":147,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":151,"conditions":152,"keywords":155,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":43},"100571573","integrating-pain-cbt-into-an-mhealth-analgesic-support-intervention-for-patients-with-chronic-pain-from-advanced-cancers-100571573","NCT06722014","Integrating Pain-CBT Into an mHealth Analgesic Support Intervention for Patients With Chronic Pain From Advanced Cancers","Inclusion Criteria:\n\n* Age ≥ 22 years\n* Patient diagnosed with an active cancer diagnosis (locally advanced solid tumor malignancy, multiple myeloma, or other advanced hematologic malignancy), either undergoing active treatment or receiving treatment for an advanced cancer or are receiving supportive\u002Fpalliative care\n* Chronic pain related to cancer or treatment (\\> pain score of 4 on a 0-10 scale)\n* Has an active prescription for at least one opioid medication to treat their cancer pain (i.e. not for post-surgical pain)\n* Own\u002Fuse a compatible smartphone (iPhone or Android)\n\nExclusion Criteria:\n\n* Patients in survivorship: patients who have completed their treatment regimens, are not actively receiving treatment for an advanced cancer, or have a cancer that is in remission\n* Cognitive impairment that would interfere with study participation, as judged by treating clinician (e.g. delirium, dementia)\n* Inability to speak English (the intervention has not yet been translated to Spanish)\n* Currently in CBT treatment\n* Enrolled in hospice\n* Currently hospitalized\n* Use of transmucosal fentanyl, given safety concerns and ongoing risk mitigation program required to prescribe these (TIRF REMS)\n* Pain primarily related to a recent surgery (within the last 2 weeks)\n* Conditions that hinder smartphone use\n* The study will exclude adults who are unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, and prisoners.","22 Years",{"count":149,"type":21},60,[24],"Smartphone Technology to Alleviate Malignant Pain (STAMP) + Cognitive Behavioral Therapy for Pain (STAMP+CBT) The purpose of the study is to develop and refine the mHealth pain-CBT app intervention and carry out a randomized pilot to test the novel mHealth (Mobile health technology) intervention, which harmonizes psychological and pharmacological support for advanced cancer pain.\n\nThe name of the study smartphone application involved in this study is:\n\n-STAMP+CBT",[153,31,154],"Pain","Advanced Cancer",[153,31,154],"2025-05-14",{"date":158,"type":36},"2025-05-16",{"date":160,"type":36},"2025-03-27",{"date":162,"type":21},"2026-10-31",{"name":164,"class":42},"Dana-Farber Cancer Institute",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":43},"100570242","postoperative-analgesia-between-paravertebral-block-and-epidural-block-in-esophageal-surgery-100570242","NCT06704698","Postoperative Analgesia Between Paravertebral Block and Epidural Block in Esophageal Surgery","Paravertebral Block With Liposomal Bupivacaine and Epidural Block With Plane Bupivacaine for Postoperative Analgesia in Esophageal Surgery: A Randomized, Non-inferiority Study","Inclusion Criteria:\n\n* American Society of Anesthesiologist physical status I-III;\n* Scheduled elective thoracoscopic esophagectomy(three-incision approach);\n* Approved participation before study.\n\nExclusion Criteria:\n\n* Patients with contraindications for local nerve block such as spinal anatomic structure abnormality or local infection of puncture area;\n* Anergic to medications used in this study;\n* Patient have chronic pain;\n* Patient receiving anticoagulants, opioids or have a history of narcotic abuse or alcohol abuse;\n* Inability to complete postoperative pain assessments or questionnaires due to communication barriers or mental disorders;","80 Years",{"count":174,"type":21},132,[24],"Prevention of postoperative pain is essential for the recovery of esophageal surgery. Epidural analgesia is a traditional and standard perioperative pain management for these patients. Beneficials of epidural analgesia have been widely established. However, there are still several potential disadvantages such as perioperative hypotension, failure of administration, rare but serious neurological complications. Ultrasound-guided regional nerve block has become a widely used technique due to its low degree of trauma and precise target of action. In combined with liposome bupivacaine (LB), a new long-acting local anesthetic, was proven to have a maximum duration of 72 hours, thus improving postoperative analgesia, reducing opioid consumption, and enhancing patient satisfaction. The aim of this study was to evaluate the efficacy of TPVB liposomal bupivacaine (LB) or plane bupivacaine (SB) for Overall Benefit of Analgesic Score (OBAS) after esophageal surgery.",[31,178,179,180,181,182,183],"Dizziness","Vomiting","Itching","Sweet Syndrome","Cold","Satisfaction, Patient","2024-12-23",{"date":186,"type":36},"2024-12-30",{"date":188,"type":36},"2024-12-03",{"date":190,"type":21},"2025-12-30",{"name":192,"class":42},"Zhejiang Cancer Hospital"]